MK-677 (ibutamoren) is an orally active, non-peptide growth hormone secretagogue studied as an investigational agent. It is not an approved medicine. This page describes hypothesized and investigational effects, not established treatments.
Overview
MK-677 is a small molecule that mimics ghrelin at the growth hormone secretagogue receptor (GHS-R1a), prompting the pituitary to release the body's own growth hormone (GH). Because of this mechanism, most interest in MK-677 centres on:
- Stimulating endogenous GH secretion via an oral compound rather than an injection.
- Downstream effects on IGF-1, the hormone that mediates much of GH's action.
- Ghrelin-driven effects such as appetite, and reported effects on sleep.
These are the mechanisms researchers study; they are not a promise of any specific cosmetic, athletic, or clinical result.
Growth hormone and IGF-1
In human studies, MK-677 has been shown to raise GH and IGF-1 levels, and because it is long-acting and orally available, that elevation can be sustained more steadily than with short-acting injectable secretagogues. This GH-raising property is the central reason it has been investigated.
- GH secretion is stimulated but remains subject to the body's feedback loops.
- Effect size and IGF-1 response vary with the individual and context.
- Sustained elevation of GH/IGF-1 is a double-edged theme, with both hypothesized benefits and metabolic concerns.
Appetite and body composition
Because MK-677 activates the ghrelin ("hunger hormone") receptor, appetite stimulation is one of its most consistent effects. That has driven research interest in settings of poor appetite or wasting, and it is also why it is discussed in the context of body composition. Some studies have examined lean mass and muscle-related endpoints, but claims about fat loss or dramatic physique change extrapolate from GH/IGF-1 biology more than from robust long-term trials in healthy adults.
How MK-677 compares to peptide secretagogues
MK-677 is often grouped with injectable secretagogue peptides because they share a receptor target, but it differs in important ways:
- Route — MK-677 is taken by mouth, whereas GHRP-2, GHRP-6, and ipamorelin are injected.
- Duration — MK-677 is longer-acting, favouring steadier GH stimulation rather than short pulses.
- Chemistry — it is a non-peptide small molecule, not a peptide.
This oral, long-acting profile is the main reason it is discussed separately from the injectable peptides that act on the same receptor.
Evidence and caveats
MK-677 has well-characterised short-term hormonal effects, but that is not the same as proven long-term benefit for appearance, performance, or aging. Key caveats:
- It is not an FDA-approved therapy in the United States.
- Raising GH/IGF-1 does not guarantee a desired downstream outcome.
- It can raise fasting glucose and reduce insulin sensitivity, a notable metabolic concern.
- Long-term safety in healthy people has not been established.